Internationale Partnersuche

Innovation & Technologie Angebot

Unique Approach for the Study of Immune System Funcionality

Country of Origin: Italy
Reference Number: TOIT20180905001
Publication Date: 13 September 2018

Summary

An Italian company can provide a unique, sensitive and specific approach for the study of Immune System Functionality through Enzyme-Linked ImmunoSPOT and Precursor with High Proliferative Capacity (PHPC) methodologies; the approach has been recently validated by the Italian Drug Agency. As a laboratory certified to conduct immunology assays within the context of Phase I clinical trials, the company is open to technical cooperation agreements, service agreements or research agreements.

Description

Within immune system functionality studies, Enzyme-Linked Immunospot (ELISpot), detects the Effector T cells cytokines secretion with an in vitro system that closely resembles the in vivo immune biology, thus allowing immune response monitoring.

ELISpot goes beyond the limits of the Eenzyme-Linked Immunosorbent Assay  methodology (ELISA), that only indirectly measures cytokines, overcomes the high cell number needed for flow cytometry and, compared to Intracellular Cytokines Staining (ICS), ELISpot offers a better evaluation of the full efficiency of cytokines secretion, as intracellular staining could monitor a protein that maybe will be not released.



ELISpot offers the best point of view for ex vivo Effector T cells monitoring, with application in:

•	Drug development

•	Vaccine development

•	Transplantation



PHPC, similarly to ELISpot, detecting the T cells cytokines secretion with an in vitro system that closely resembles the in vivo immune biology, allows immune response monitoring in many fields of immune system functionality studies.

PHPC offers the best point of view for ex vivo monitoring of Central Memory T cells, again with application in:

•	Drug development

•	Vaccine development

•	Transplantation



Application: nowadays, ELISpot offers the best point of view for ex vivo Effector T cells monitoring, with application in:

•	DRUG DEVELOPMENT: ELISpot permits to assess the immunogenicity of biotherapeutics avoiding molecules that could trigger an unwanted activation of immune system.



•	VACCINE DEVELOPMENT: ELISpot permits to evaluate the immune response induced after administration of vaccine candidates.

o	Cancer Vaccine (Butterfield et al. 2014)

o	Infectious Disease Vaccine (Calarota et al. 2007)



•	TRANSPLANTATION: Assessment of donor-specific T cell immunity pre- and post-transplant permit to identify patient with major risk of rejection and to identify immunosuppressive therapy.



The company offers its own developments in methodologies for advancements in the mentioned fields and is ready for cooperation agreements.

Advantages and Innovations

The company was recently inserted in the list of authorized laboratory certified to conduct immunology assays within the context of Phase I clinical trials. The company can perform these immunology assays as a fee-for-service for any research center, company or university, interested in evaluating immune response in human samples deriving from drug development (e.g. immune-oncology drugs) or vaccine development programs.

Stage Of Development

Field tested/evaluated

Requested partner

The owner of the profile is looking for companies, research centers or universities willing to test immune response in human samples derived from drug development or vaccine development programs in infectious disease (viral infection or parasitic infections), oncology, transplantation programs, through Technical cooperation agreements, research cooperation agreements or service agreements.